IMAGING PROTOCOLS

• US 20140193336A1
• Filed: 01/06/2014
• Published: 07/10/2014
• Est. Priority Date: 07/19/2005
• Status: Abandoned Application

• Current Assignee: Spectrum Dynamics Medical Ltd
• Original Assignee: Biosensors International Group, Ltd.
• Inventors: ROUSSO, Benny, Nir, Yael, Nagler, Michael, Bronshtine, Zohar, Vallabhajosula, Shankar, Ben-Haim, Shlomo, Ben-Haim, Simona, Dickman, Dalia
• Application Number:
  US14/147,682
• Publication Number:
  US 20140193336A1
• Time in Patent Office: Days
• US Class Current: 424/1.65
• CPC Class Codes: A61B 6/037 Emission tomography
• CPC Class Codes: A61B 6/4258 for detecting non x-ray radiation, e.g. gamma radiation A61B6/037 takes precedence
• CPC Class Codes: A61B 6/503 for diagnosis of the heart
• CPC Class Codes: A61K 51/0476 complexes from monodendate ligands, e.g. sestamibi
• CPC Class Codes: G01T 1/1644 using an array of optically separate scintillation elements permitting direct location of scintillations G01T1/1645 takes precedence

Abstract

Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence:

• • (a) administering to a subject about 3 mCi Tl201 thallous chloride;
  • (b) allowing said subject to rest;
  • (c) radioimaging a heart of said subject;
  • (d) subjecting said subject to a physical stress;
  • (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and
  • (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

Claims

1. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 3 mCi Tc99m sestamibi;

(b) radioimaging a heart of said subject;

(c) subjecting said subject to a pharmacological stress;

(d) administering to said subject at a peak of said pharmacological stress an additional radiopharmaceutical;

(e) radioimaging said heart of said subject; and

(f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

2. The method of claim 1, wherein said additional radiopharmaceutical comprises about 3 mCi Tl201 thallous chloride.

3. The method of claim 1, wherein said additional radiopharmaceutical comprises an additional dose of Tc99m sestamibi.

4. The method of claim 1, wherein step (b) is effected immediately following step (a).

5. The method of claim 1, wherein step (b) is within 2 minutes.

6. The method of claim 1, wherein step (c) is effected immediately following step (b).

7. The method of claim 1, wherein step (d) is effected within 2 minutes following step (c).

8. The method of claim 1, wherein step (e) is effected immediately following step (d).

9. The method of claim 1, wherein step (e) is within 4 minutes.

10. The method of claim 1, wherein step (f) is effected within 4 hours following step (e).

11. The method of claim 1, wherein step (f) is within 6 minutes.

12. The method of claim 1, wherein said pharmacological stress is adenosine or dipyridamole.

13. The method of claim 1, effected as described in Table 8.

14. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 0.3 mCi Tl201 thallous chloride;

(b) radioimaging a heart of said subject;

(c) subjecting said subject to a physical stress;

(d) administering to said subject at a peak of said physical stress about 3 mCi Tc99m sestamibi; and

(e) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

15. The method of claim 14, wherein step (b) is effected within 10-15 minutes following step (a).

16. The method of claim 14, wherein step (b) is within 15 minutes.

17. The method of claim 14, wherein step (c) is immediately following step (b).

18. The method of claim 14, wherein step (e) is effected within 30-60 minutes following step (d).

19. The method of claim 14, wherein step (e) is within 15 minutes.

20. The method of claim 14, effected as described in Table 14.